Quviviq (daridorexant) is Idorsia’s dual orexin receptor antagonist for insomnia, approved in January 2022 and sold as a Schedule IV controlled substance in 25 mg and 50 mg tablets. It competes directly with Eisai’s Dayvigo (lemborexant) and Merck’s older Belsomra, and the three are priced far enough apart that the choice is worth several hundred dollars a year to a cash payer.
Every figure below was pulled fresh on September 3, 2026 from CMS pricing files and from the manufacturers’ own statutory price disclosures and savings-program terms. This is a money and paperwork guide, not medical advice, and nothing here speaks to which drug is right for you.
What Does Quviviq Cost Without Insurance?
All three of these drugs are dispensed as 30-tablet packages, so one package is a month of nightly dosing and is the unit every price is quoted in. Within each brand, the strengths cost the same. The list-price rows come from the manufacturers’ wholesale acquisition cost disclosures filed under state price-transparency laws. The acquisition-cost rows are CMS’s National Average Drug Acquisition Cost survey, which measures what retail pharmacies actually pay wholesalers, effective August 19, 2026.
| Price point | Low | Average / typical | High |
|---|---|---|---|
| Quviviq 25 mg, 30 tablets | $501.48 | $520.09 | $524.35 |
| Quviviq 50 mg, 30 tablets | $501.13 | $520.09 | $524.35 |
| Quviviq, per tablet | $16.70 | $17.34 | $17.48 |
| Dayvigo 5 mg, 30 tablets | $347.41 | $362.48 | $363.00 |
| Dayvigo 10 mg, 30 tablets | $347.38 | $362.48 | $363.00 |
| Dayvigo, per tablet | $11.58 | $12.08 | $12.10 |
| Belsomra, any strength, 30 tablets (NADAC acquisition) | $455.96 | $456.22 | $456.41 |
| Medicare Part D average per fill, 2024 (Quviviq) | $526.95 | $526.95 | $526.95 |
| Medicare Part D average per fill, 2024 (Dayvigo) | $362.33 | $362.33 | $362.33 |
| QSavings card, first fill (commercial insurance only) | $0 | $0 | $0 |
| QSavings card, refills (commercial insurance only) | $25 | $25 | $25 |
| Dayvigo Instant Savings Card (commercial insurance only) | $35 | $35 | $135 |
The honest cross-source range for 30 tablets of Quviviq is about $501 to $524, and the sources agree closely. Idorsia’s disclosed wholesale acquisition cost is $524.35, last updated January 1, 2026. The published cash price on Drugs.com read September 3, 2026 is $520.09. NADAC’s per-tablet figure of about $16.71 works out to roughly $501 for 30 tablets. CMS’s Part D data for 2024 lands at $526.95 per claim, which is within 1% of the list price.
Treat the low end as a floor rather than a quote. NADAC measures what the pharmacy paid, not what it charges you, and stores add markup and a dispensing fee on top. Cash quotes on brand drugs also move between pharmacies on the same day, so price the exact strength and quantity at three stores before filling.
Dayvigo cost, priced side by side
If you searched for Dayvigo cost separately, the answer is that Dayvigo is meaningfully cheaper than Quviviq in cash terms. Eisai’s Colorado disclosure, source-dated June 25, 2026, lists a wholesale acquisition cost of $363.00 per 30-count bottle at both 5 mg and 10 mg. Drugs.com puts the published cash price at $362.48 for 30 tablets, and NADAC has pharmacies acquiring it for about $347.
That is a difference of roughly $161 a month against Quviviq, or about $1,930 over a year of nightly use. Belsomra sits between them, with NADAC acquisition around $456 for 30 tablets. Our Belsomra cost guide covers Merck’s list price and coupon terms in detail.
What Drives the Price
No generic exists for either drug. FDA’s Drugs@FDA database contains only NDA 214985 for daridorexant and NDA 212028 for lemborexant, with no abbreviated applications filed for either molecule at any stage. Eisai’s Colorado disclosure states outright that there are currently no generic prescription drugs in the same therapeutic class as Dayvigo. Nothing in this class is going cheap in the near term.
Flat pricing across strengths. Idorsia charges the same $524.35 for a 30-count package of 25 mg or 50 mg, and NADAC prices the two within two cents per tablet. Eisai does the same at 5 mg and 10 mg. On most medications a dose reduction saves money. Here it saves nothing, so there is no cost argument for a lower strength.
Both are Schedule IV controlled substances. That caps refills and rules out the 90-day fills that normally cut per-unit cost on a chronic medication. You are buying 30 tablets at a time, about twelve times a year, at full price each time.
Launch age. Quviviq came to market in 2022, Dayvigo in 2020, and Belsomra in 2014. Newer brand launches generally price above the incumbents in a class, and that is exactly the pattern here: the newest drug is the most expensive and the middle-aged one is the cheapest.
Which pharmacy you use. Brand cash quotes on controlled substances vary by store more than people expect, and independents in low-cost markets sometimes undercut national chains. The spread between the cheapest and most expensive pharmacy in a metro area is often larger than any discount card will produce.
Cash Price vs. Insurance
For a commercially insured patient, using insurance wins on Quviviq, because the QSavings card can take the first 30-day fill to $0 and later refills to $25. That is a real benefit worth several hundred dollars a month.
For an uninsured reader it is worth nothing, and Idorsia says so in writing. The QSavings terms and conditions require commercial insurance whose coverage does not pay the full cost of the prescription, exclude anyone on Medicare Part D, Medicaid, Medigap, VA or Department of Defense coverage, and then state under Restrictions: “This offer is not valid for Cash-Paying Patients.” The terms also forbid combining the card with any other discount or prescription savings card. Questions go to 1-866-303-1222.
There is no published patient assistance program behind it either. Drugs.com’s Quviviq page, which lists manufacturer assistance programs when they exist, records none for the drug. That combination, a copay card locked to commercial insurance and no free-medicine program, is the single most useful fact on this page for a self-pay patient.
Dayvigo is structured differently and slightly better. Eisai’s Instant Savings Card also requires commercial insurance and states that cash-paying patients are excluded, but it has two tiers: as little as $35 for a 30-day supply if your plan covers Dayvigo, and as little as $135 if you have commercial insurance with no Dayvigo coverage. The card is limited to 30 tablets per fill and 12 uses a year, and it expires March 31, 2027. Separately, Eisai runs a Dayvigo Patient Assistance Program that provides the drug at no cost to patients who meet its criteria, reached at 1-866-349-3026. That program does exist for the uninsured, which Idorsia’s does not.
Prior authorization is the usual friction point even with coverage. Many plans require you to try a cheap generic sedative first. If your plan denies the drug outright, you are functionally a cash payer, and the section below applies to you.
How to Pay Less
Ask your prescriber to price the whole class before you commit. The three orexin antagonists are priced $161 a month apart at list, and the cheapest is not the newest. If your prescriber is flexible on which one you start, that single conversation is worth more than every discount card combined. Ask specifically about Dayvigo, then about the older generics, and let the answer be clinical rather than cost-driven.
Call the Dayvigo Patient Assistance Program if you are uninsured. Eisai’s patient support site says the program provides Dayvigo at no cost to patients in need who meet eligibility criteria, with an enrollment form to download and a line at 1-866-349-3026. There is no equivalent published program for Quviviq, so if free medicine is the goal, this is the door that is actually open.
Run a free discount card at three pharmacies. The gap between the cheapest and most expensive pharmacy on a brand-only controlled substance is often the biggest single saving available to a cash payer. Compare the two big free cards in our guide to GoodRx vs. SingleCare, and remember that the QSavings card cannot be combined with one anyway.
Check a community health center. Federally qualified health centers charge on a sliding scale and many operate in-house 340B pharmacies that price brand drugs far below retail. Our guide to free and sliding-scale clinics explains how to find one and what to bring.
Make sure you are treating the right problem. If the underlying issue is sleep-disordered breathing rather than primary insomnia, a monthly brand hypnotic is an expensive way to not fix it. Our guides to sleep study costs and CPAP machine costs cover the diagnostic and equipment path for a cash payer, and oral appliance therapy covers the alternative to a machine.
Verify a quoted price before you pay it. Cash quotes on brand-only drugs vary far more than most people expect. Our fair price checker shows the current national range so you can tell whether the number you were given is out of line, and our negotiation script gives you the wording if a pharmacy or clinic bill is already in dispute.
The Bottom Line
Quviviq is a roughly $520-a-month drug in cash terms, and with no generic daridorexant filed at FDA it will stay there indefinitely. The 25 mg and 50 mg strengths cost the same, so there is no dose-shopping angle.
If you are uninsured, take Idorsia’s savings headline at face value only after reading the fine print: the QSavings card is void for cash payers by its own terms and there is no patient assistance program behind it. Price Dayvigo, which is about $161 a month cheaper and does have a no-cost patient assistance program, and price Belsomra as the third option before you settle. If a fill has already gone to collections or a bill is in dispute, start with our guide to negotiating medical bills.